January 8, 2019
Daiichi Sankyo has earned exclusive rights to commercialize US upstart Esperion Therapeutics’ first-in-class hypercholesterolemia treatment bempedoic acid and its combination pill with ezetimibe in European countries. The Japanese drug major said on January 7 that it entered into a licensing...read more